MP09-Neurofarmacología del Dolor

EST64454: a Highly Soluble sigma(1) Receptor Antagonist Clinical Candidate for Pain Management

JOURNAL OF MEDICINAL CHEMISTRY, 2020;

FI:6,205; D1

Editorial: Sigma Receptors

FRONTIERS IN PHARMACOLOGY, 2020;

FI:4,225; Q1

Editorial: Mechanisms and New Targets for the Treatment of Chronic Pain

FRONTIERS IN PHARMACOLOGY, 2020;

FI:4,225; Q1

Melatonin Improves Mitochondrial Dynamics and Function in the Kidney of Zucker Diabetic Fatty Rats

JOURNAL OF CLINICAL MEDICINE, 2020;

FI:3,303; Q1

Binge-Like, Naloxone-Sensitive, Voluntary Ethanol Intake at Adolescence Is Greater Than at Adulthood, but Does Not Exacerbate Subsequent Two-Bottle Choice Drinking

FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2020;

FI:2,512; Q2

Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and sigma(1) receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019;

FI:4,833; D1

A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer

PHARMACOLOGICAL RESEARCH, 2019;

FI:5,574; D1

Sigma-1 Receptor Inhibition Reduces Neuropathic Pain Induced by Partial Sciatic Nerve Transection in Mice by Opioid-Dependent and – Independent Mechanisms

FRONTIERS IN PHARMACOLOGY, 2019;

FI:3,845; Q1

Prevalence and risk factors associated with fatal adverse drug reactions among patients admitted at a Spanish teaching hospital

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019;

FI:3,66; Q1

Modulation by Sigma-1 Receptor of Morphine Analgesia and Tolerance: Nociceptive Pain, Tactile Allodynia and Grip Strength Deficits During Joint Inflammation

FRONTIERS IN PHARMACOLOGY, 2019;

FI:3,845; Q1

Targeting immune-driven opioid analgesia by sigma-1 receptors: Opening the door to novel perspectives for the analgesic use of sigma-1 antagonists

PHARMACOLOGICAL RESEARCH, 2018;

FI:4,897; D1

(+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties

JOURNAL OF MEDICINAL CHEMISTRY, 2018;

FI:6,253; D1

Contilisant, a Tetratarget Small Molecule for Alzheimer’s Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile

JOURNAL OF MEDICINAL CHEMISTRY, 2018;

FI:6,253; D1

Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic sigma Receptor Ligands with Exocyclic Amino Moiety

JOURNAL OF MEDICINAL CHEMISTRY, 2018;

FI:6,253; D1

Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling

CELL REPORTS, 2018;

FI:8,032; Q1

Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia

NEUROPHARMACOLOGY, 2017;

FI:5,012; D1

Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017;

FI:9,661; D1

Paclitaxel-loaded hollow-poly(4-vinylpyridine) nanoparticles enhance drug chemotherapeutic efficacy in lung and breast cancer cell lines

NANO RESEARCH, 2017;

FI:7,354; D1

Effects of Tetrodotoxin in Mouse Models of Visceral Pain

MARINE DRUGS, 2017;

FI:3,503; Q1

Roles for CD8(+) T Cells and IL-10 in the Resolution of Paclitaxel-Induced Neuropathic Pain

JOURNAL OF NEUROSCIENCE, 2017;

FI:5,988; Q1

Sigma-1 Receptor Agonism Promotes Mechanical Allodynia After Priming the Nociceptive System with Capsaicin

SCIENTIFIC REPORTS, 2016;

FI:5,228; Q1

Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells

SCIENTIFIC REPORTS, 2016;

FI:5,228; Q1

Distinguishing subgroups among mu-opioid receptor agonists using Na+,K+-ATPase as an effector mechanism

EUROPEAN JOURNAL OF PHARMACOLOGY, 2016;

FI:2,73; Q2

Analysis of food advertising to children on Spanish television: probing exposure to television marketing

ARCHIVES OF MEDICAL SCIENCE, 2016;

FI:1,812; Q2

Maternal, fetal and perinatal alterations associated with obesity, overweight and gestational diabetes: an observational cohort study (PREOBE)

BMC PUBLIC HEALTH, 2016;

FI:2,209; Q2

ACUTE CONFUSIONAL SYNDROME INDUCED BY MOXIFLOXACIN IN AN ELDERLY MAN

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015;

FI:4,572; D1

Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats

JOURNAL OF PINEAL RESEARCH, 2015;

FI:9,6; D1

Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research

CURRENT MEDICINAL CHEMISTRY, 2015;

FI:3,853; D1

Brown adipose tissue and novel therapeutic approaches to treat metabolic disorders

TRANSLATIONAL RESEARCH, 2015;

FI:5,03; D1

The clinical heterogeneity of coenzyme Q(10) deficiency results from genotypic differences in the Coq9 gene

EMBO MOLECULAR MEDICINE, 2015;

FI:8,665; D1

Inmunoterapia e inhibición del receptor sigma-1 (σ1) como estrategia terapéutica para el alivio del dolor en la artritis reumatoide

Financiador: FUNDACIÓN PÚBLICA PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL ALEJANDRO OTERO (FIBAO)

Número de expediente: INTRAIBS-2020-09

Tiempo de ejecución: 01/01/2021 - 31/12/2021

IP: FRANCISCO RAFAEL NIETO LOPEZ

La inhibición del receptor sigma-1: una nueva estrategia para el tratamiento del dolor postoperatorio

Financiador: AGENCIA ESTATAL DE INVESTIGACIÓN

Número de expediente: PID2019-108691RB-I00

Tiempo de ejecución: 01/06/2020 - 30/05/2024

IP: ENRIQUE JOSE COBOS DEL MORAL

Determinantes neurobiológicos y conductuales en el consumo de alcohol tipo binge en ratas hembra y macho adolescentes: papel de los receptores sigma-1 y su potencial uso como tratamiento farmacológico

Financiador: MINISTERIO DE SANIDAD

Número de expediente: PND-2020-049

Tiempo de ejecución: 01/01/2021 - 31/12/2023

IP: CRUZ MIGUEL CENDAN MARTINEZ

Evaluación de la Eficacia Analgésica de Un Nuevo Sistema Electromagnético Transcutáneo en Patologías Asociadas A Dolor Neuropático Periferico

Financiador: CONSEJERÍA DE SALUD

Número de expediente: PIN-0505-2016

Tiempo de ejecución: 01/01/2017 - 31/12/2018

IP: RAFAEL GALVEZ MATEOS

Estudio aleatorizado, doble ciego, controlado con un placebo y en grupos paralelos para evaluar la eficacia y la seguridad del BIIB074 ensujetos condolor neuropatico por radiculopatia lumbosacra

Financiador: CONVERGENCE PHARMACEUTICALS LIMITED

Tipo de prueba: ENSAYO CLINICO COMERCIAL

Tiempo de ejecución: 20/04/2017 - 30/05/2018

IP: RAFAEL GALVEZ MATEOS

An Uncontrolled, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Financiador: BIOGEN IDEC LIMITED

Tipo de prueba: ENSAYO CLINICO COMERCIAL

Tiempo de ejecución: 08/11/2017 - 30/04/2019

IP: RAFAEL GALVEZ MATEOS

Ensayo doble ciego, controlado con placebo, aleatorizado, de busquedad de dosis para determinar la seguridad y eficacia de tres niveles de dosis de EMA401 para reducir la puntuacion de intensidad del dolor promedio a las 24 horas en pacientes con neuralgia posherpetica (EMPHENE)

Financiador: NOVARTIS FARMACEUTICA, S.A.

Tipo de prueba: ENSAYO CLINICO COMERCIAL

Tiempo de ejecución: 21/07/2017 - 30/09/2019

IP: RAFAEL GALVEZ MATEOS